Provided by Tiger Trade Technology Pte. Ltd.

Galectin Therapeutics

3.15
-0.0300-0.94%
Post-market: 3.150.00000.00%16:10 EDT
Volume:268.55K
Turnover:855.95K
Market Cap:203.09M
PE:-5.33
High:3.31
Open:3.15
Low:3.11
Close:3.18
52wk High:7.13
52wk Low:1.12
Shares:64.47M
Float Shares:44.93M
Volume Ratio:0.54
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5905
EPS(LYR):-0.7575
ROE:-3727.94%
ROA:-87.09%
PB:-1.61
PE(LYR):-4.16

Loading ...

Galectin Therapeutics Secures Additional $10 Million Line of Credit from Richard E. Uihlein

Reuters
·
Dec 19, 2025

10X Fund, L.P. Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Dec 18, 2025

Galectin Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 17, 2025

Director Harold H. Shlevin Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Dec 17, 2025

Galectin Therapeutics Director Harold H. Shlevin Reports Disposal of Common Shares

Reuters
·
Dec 10, 2025

Galectin Therapeutics Inc. held annual shareholder meeting

Reuters
·
Dec 08, 2025

Galectin Therapeutics unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy

Reuters
·
Dec 06, 2025

10X Fund, L.P. Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Dec 05, 2025

Galectin Therapeutics Inc. Publishes Transcript of NAVIGATE Trial Update Event

Reuters
·
Dec 04, 2025

Galectin Therapeutics CEO Joel Lewis Reports Disposal of Common Shares

Reuters
·
Nov 20, 2025

Galectin Therapeutics Chief Medical Officer Jamil Khurram Reports Disposal of Common Shares

Reuters
·
Nov 15, 2025

Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment

TIPRANKS
·
Nov 15, 2025

Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update

GlobeNewswire
·
Nov 14, 2025

Galectin Therapeutics: Submitted Navigate Data Package to FDA and Requested Feedback on Proposed Next Steps, Guidance Anticipated by Year-End

THOMSON REUTERS
·
Nov 14, 2025

Galectin Therapeutics Inc: Qtrly Loss per Share $0.13

THOMSON REUTERS
·
Nov 14, 2025

Galectin Therapeutics reports Q3 2025 financial results and updates on belapectin trial data

Reuters
·
Nov 14, 2025

10X Fund, L.P. Reports Disposal of Galectin Therapeutics Inc. Common Shares

Reuters
·
Nov 13, 2025

Galectin Therapeutics CFO Jack W. Callicutt Reports Disposal of Common Shares

Reuters
·
Nov 13, 2025

Galectin Therapeutics unveils pipeline progress on galectin-3 inhibitor for MASH cirrhosis and cancer

Reuters
·
Nov 10, 2025

Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting

GlobeNewswire
·
Nov 10, 2025